 |
In a Phase 2 or Phase 3 trial, you might have twenty different clinical sites collecting blood. If Site A uses a different centrifuge speed than Site B, or if Site C leaves the blood on the bench for four hours longer than Site D, your downstream data will be incredibly noisy.
Read More
One of the most frustrating scenarios in bioanalytics is the "High Background" plate. You run a functional assay, and your negative control wells are full of non-specific activity. Is it the assay? Is it the reagents?
Read More
In multi-center clinical trials, the standard logistics model involves collecting blood at the clinical site, shipping it overnight to a central lab, and processing it the next day (24+ hours post-draw).
Read More
At Accelevir, we focus on ultra-rare target detection and have become hyper-vigilant about incoming PBMC Quality which includes viability, recovery and Flow based immuno-profiling. As expected we find that PBMC quality is one of the most critical elements of end-point readouts and triage decisions for clinical trial design and outcome measurements.
Read More
In the development of biologics and advanced therapies, the industry has historically focused heavily on the humoral immune response. Screening for Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) is a standard path for regulatory approval.
Read More
In the early days of Cell Therapy, "Identity" was the primary bioanalytical hurdle. If you were manufacturing a CAR-T therapy, the main question was: Are these cells CD3+? Are they expressing the CAR?
Read More
Accelerating AAV, Lentiviral, and mRNA Programs from Discovery to the Clinic.
Read MoreIn immuno-oncology and autoimmune drug development, knowing if a drug works is only half the battle. You also need to know how it is shaping the patient's immune system. Is it expanding the right T-cell subsets? Is it triggering the intended functional activity?
Read More
The next generation of CAR-T therapy is moving in vivo, utilizing Lipid Nanoparticles (LNPs) and mRNA to engineer immune cells directly inside the patient. While this approach promises to democratize access to cell therapy, it introduces a unique set of bioanalytical challenges—from tracking transient mRNA expression to monitoring innate immune activation.
Read More
In the rapidly evolving landscape of cell and gene therapy, the margin for error is non-existent. As therapies move from preclinical models to human clinical trials, the need for absolute quantification of genetic material becomes critical. Traditional qPCR, while useful, often lacks the sensitivity and precision required for the complex matrices and low-abundance targets found in clinical samples.
Read More